Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Masahiro OkadaDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Bavani SubramaniamCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.ORCID 0009-0000-9667-7742
Baobao GengState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
Jangham JungDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0003-2806-3698
Bohyeon YuDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0002-1892-7790
Felicia LinDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Yu FuState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.ORCID 0009-0002-3497-6207
Yishu WangState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
Weiqiang YuState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.ORCID 0009-0000-2081-4173
Sandra LaternserChildren's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Nalin GuptaDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0001-9539-7052
Sabine MüllerDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Lin WangState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
Aaron DiazDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID 0000-0001-9059-9501
Javad NazarianChildren's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1951-9828
Funding
An informatics framework for single-cell multi-omics from clinical specimensR01LM013897 · NLM · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aaron Antonio Diaz · 2022 to 2026
$1.8M
Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effectsR01CA246722 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GUPTA, NALIN · 2020 to 2024
$1.8M
Basic Research Program of Jiangsu BK20240025CAMS Innovation Fund for Medical Sciences 2022-I2M-1-024CAMS Innovation Fund for Medical Sciences 2022-I2M-2-004CAMS Innovation Fund for Medical Sciences 2023-I2M-2-005DIPG DMG Research Funding Alliance 30008097Gusu Innovation and Entrepreneurship Leading Talents Program ZXL2024381NCI NIH HHS R01 CA246722NCI NIH HHS R01CA246722NLM NIH HHS R01 LM013897NLM NIH HHS R01LM013897Rising Tide Foundation CCR-20-500
6 · The paper itself
Abstract
backgroundImipridone ONC201 is the first FDA-approved therapy for H3K27-altered diffuse midline glioma; however, clinical responses remain limited. Defining tumor-intrinsic determinants and microenvironmental, extrinsic factors that shape sensitivity or resistance to imipridones will identify actionable therapeutic opportunities and inform improved clinical strategies.
methodsTo identify mechanisms of imipridone resistance, we obtained postmortem brain tissue from DMG patients who had received imipridones and/or standard care. Single-nucleus RNA and open-chromatin sequencing were performed on N = 22 cases. Immunofluorescence-based myeloid phenotyping was performed on N = 46 cases. Mitochondrial copy-number analysis was performed on N = 19 cases. Validation of imipridone sensitivity, its effect on mitochondrial density, and its synergy with inhibition of mitochondrial biogenesis were assessed in DMG primary cells.
resultsWe established a single-cell RNA/open-chromatin atlas from postmortem DMG cases and found imipridone treatment resulting in regressed mesenchymal transition, reduced myeloid-derived suppressive cells, and reversed aberrant H3K27-altered enhancer activity. Resistant tumors showed increased mitochondrial density, turnover, and membrane potential. Mitochondrial biogenesis and PPARGC1A emerged as resistance biomarkers and actionable targets.
conclusionsThese studies implicate mitochondrial biogenesis as a biomarker of imipridone resistance and a focus for the development of combinatorial strategies to provide effective therapeutic options for a challenging pediatric brain tumor.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy. · full record | OpenQuestion